Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Chantelle Anandan is active.

Publication


Featured researches published by Chantelle Anandan.


PLOS Medicine | 2011

The impact of eHealth on the quality and safety of health care: a systematic overview.

Ashly Black; Josip Car; Claudia Pagliari; Chantelle Anandan; Kathrin Cresswell; Tomislav Bokun; Brian McKinstry; Rob Procter; Azeem Majeed; Aziz Sheikh

Aziz Sheikh and colleagues report the findings of their systematic overview that assessed the impact of eHealth solutions on the quality and safety of health care.


Allergy | 2010

Is the prevalence of asthma declining? Systematic review of epidemiological studies.

Chantelle Anandan; Ulugbek Nurmatov; O C P van Schayck; Aziz Sheikh

To cite this article: Anandan C, Nurmatov U, van Schayck OCP, Sheikh A. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy 2010; 65: 152–167.


Allergy | 2009

Omega 3 and 6 oils for primary prevention of allergic disease: systematic review and meta‐analysis

Chantelle Anandan; Ulugbek Nurmatov; Aziz Sheikh

Background:  There is conflicting evidence on the use of omega 3 and omega 6 supplementation for the prevention of allergic diseases. We conducted a systematic review evaluating the effectiveness of omega 3 and 6 oils for the primary prevention of sensitization and development of allergic disorders.


Journal of the Royal Society of Medicine | 2009

Epidemiology and disease burden from allergic disease in Scotland: analyses of national databases.

Chantelle Anandan; Ramyani Gupta; Colin R Simpson; Colin Fischbacher; Aziz Sheikh

Summary Background There are ongoing concerns about the quality of care provided to patients with allergic disorders in Scotland, but there are relatively few reliable data on the overall disease burden. We sought to: (1) describe the incidence, prevalence and outcome of allergic disorders; (2) estimate healthcare burden and costs; and (3) investigate ethnic variations in the epidemiology and outcomes from allergic disorders in Scotland. Methods Data sources: national surveys; primary care data; prescribing and medication data; hospital admissions data and mortality data. Results Allergic disorders are extremely common in Scotland, affecting about one in three of the population at some time in their lives. Incidence was highest for eczema (10.2 per 1000 registered patients). Over 4% of all GP consultations and 1.5% of hospital admissions were for allergic disorders. There were 100 asthma deaths in 2005 (20 per million people). Direct healthcare costs for allergic disorders were an estimated £130 million per year, the majority of these being incurred in primary care and related to asthma. Conclusions Allergic disorders are common in Scotland and given the very high proportion of children now affected, the high disease burden associated with these conditions is likely to persist for many decades.


international conference on communications | 2009

The Impact of eHealth on the Quality and Safety of Healthcare

Azeem Majeed; Ashly Black; Josip Car; Chantelle Anandan; Kathrin Cresswell; Brian McKinstry; Claudia Pagliari; Rob Procter; Aziz Sheikh

There is considerable interest in using information technology (IT) to enhance the quality and safety of healthcare. We undertook a systematic literature review to assess the impact of eHealth applications on the quality and safety of healthcare. We retrieved 46,349 potentially relevant publications, from which we selected 67 relevant systematic reviews for inclusion. The literature was found to be poorly collated and of variable quality in its methodology, reporting and utility. We categorised eHealth applications into three main areas: i). storing, managing and transmission of data; ii). supporting clinical decision-making; and iii). facilitating care from a distance. We found that relative to the potential benefits noted within the literature, little empirical evidence exists in support of these applications. Of the few studies revealing the clearest evidence of benefits, many are from academic clinical centres where developers of new applications have also been directly associated with their evaluation. It is therefore unclear how effective these applications would be if deployed outside the environment in which they were developed. Our review of the impact of eHealth applications on quality and safety of healthcare demonstrated a vast gap between the postulated and empirically demonstrated benefits. In addition, there is a lack of robust research on risks and costs. Consequently, the cost-effectiveness of these interventions has yet to be demonstrated.


PLOS ONE | 2012

Prevalence of allergic disorders among primary school-aged children in Madinah, Saudi Arabia: two-stage cross-sectional survey.

Mahmoud Nahhas; Raj Bhopal; Chantelle Anandan; Rob Elton; Aziz Sheikh

Background There are limited data on the epidemiology of allergic disorders in Saudi Arabia. Such data are needed for, amongst other things, helping to plan service provision at a time when there is considerable investment taking place in national healthcare development. We sought to estimate the prevalence of atopic eczema, allergic rhinitis and asthma in primary school children in Madinah, Saudi Arabia. Methods and Findings We conducted a two-stage cross-sectional survey of schoolchildren in Madinah. Children were recruited from 38 randomly selected schools. Questionnaires were sent to the parents of all 6,139 6–8 year old children in these schools. These parental-completed questionnaires incorporated questions from the International Study of Asthma and Allergies in Childhood (ISAAC), which had previously been validated for use in Arab populations. We undertook descriptive analyses, using the Generalized Estimating Equation (GEE) to calculate 95% confidence intervals. The overall response rate was 85.9% (n = 5,188), 84.6% for girls and 86.2% for boys, respectively. Overall, parents reported symptoms suggestive of a history of eczema in 10.3% (95%CI 9.4, 11.4), rhinitis in 24.2% (95%CI 22.3, 26.2) and asthma in 23.6% (95%CI 21.3, 26.0) of children. Overall, 41.7% (95%CI 39.1, 44.4) of children had symptoms suggestive of at least one allergic disorder, with a substantial minority manifesting symptoms indicative of co-morbid allergic disease. Comparison of these symptom-based prevalence estimates with reports of clinician-diagnosed disease suggested that the majority of children with eczema and asthma had been diagnosed, but only a minority (17.4%) of children had been diagnosed with rhinitis. International comparisons indicated that children in Madinah have amongst the highest prevalence of allergic problems in the world. Conclusions Symptoms indicative of allergic disease are very common in primary school-aged children in Madinah, Saudi Arabia, with figures comparable to the highest risk regions in the world.


Clinical & Experimental Allergy | 2006

Exploiting the potential of routine data to better understand the disease burden posed by allergic disorders

Chantelle Anandan; Colin R Simpson; Colin Fischbacher; Aziz Sheikh

The Department of Health and Scottish Executive are currently undertaking independent reviews of allergy services in England (and Wales) and Scotland. Each review will assess the disease burden posed by allergic problems, involving secondary analyses of routine National Health Service (NHS) datasets. Major suggestions for re‐structuring and/or re‐focusing the NHS efforts to better deal with allergic disease are anticipated. The UK has some of the best datasets of routine health data in the world, but despite their strengths, they have important limitations. These include gaps in data collection, particularly in relation to monitoring of Accident & Emergency and out‐patient consultations, and in‐patient prescribing, thereby resulting in considerable under‐estimates of hospital workload. The current gaps in service monitoring are likely to under‐estimate the burden and workload associated with allergic problems, particularly in secondary care. One major limitation of existing data sources is the general inability to link individual patient level data between different datasets. By unlocking this potential there are very considerable potential gains to be made. Data linkage techniques currently being developed in the UK offer exciting new possibilities of looking across the primary‐, secondary‐ and tertiary‐care interfaces and also assessing short‐and long‐term social and educational outcomes in relation to allergic disorders. The current reviews of allergy services being undertaken need to be cognisant of these inherent limitations of existing data sources and would do well to recommend strategic initiatives that could enhance the availability, accessibility and quality of these datasets. Ideally, this should include investment in central data repositories staffed by teams with the necessary technical and statistical expertise, which would also take responsibility for progressing data linkage capabilities.


Clinical & Experimental Allergy | 2007

Will Systematized Nomenclature of Medicine‐Clinical Terms improve our understanding of the disease burden posed by allergic disorders?

Colin R Simpson; Chantelle Anandan; Colin Fischbacher; K. Lefevre; Aziz Sheikh

Analysis of data collected through the use of high‐quality computerized systems is vital if we are to understand the health burden from allergic disease. Coding systems currently used, such as the World Health Organizations International Classification of Diseases and the Read system, have however been criticized as being unduly restrictive and hence inadequate for the detailed coding of allergic problems. Greater granularity of coding can be achieved by using the Systematized Nomenclature of Medicine‐Clinical Terms (SNOMED‐CT) system, which will be adopted by several countries including the United States and United Kingdom. Before the introduction of SNOMED‐CT, it is important that several issues are resolved, including ensuring that adequate mapping occurs from existing systems, that the SNOMED‐CT is trialled before general implementation, and that training is provided for users new to coding as part of their clinical practice. Of particular importance is that the allergy fraternity bring to light any gaps in allergy coding through the creation of a working group to advise the newly formed International Healthcare Terminology Standards Development Organisation. There is also a role for allergy experts, working in conjunction with government agencies and professional bodies, to determine a recommended set of codes, which will obviate some of the inevitable challenges raised by a very fluid coding structure for those wishing to undertake secondary analysis of health care datasets.


BMC Medical Research Methodology | 2013

Protocol for a systematic review and individual patient data meta-analysis of prognostic factors of foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS)

Fay Crawford; Chantelle Anandan; Francesca M. Chappell; Gordon Murray; Jacqueline F. Price; Aziz Sheikh; Colin R Simpson; Martin Maxwell; Gerard Stansby; Matthew J Young; Caroline A. Abbott; Andrew J.M. Boulton; Edward J. Boyko; Thomas Kastenbauer; Graham P. Leese; Matteo Monami; M. Monteiro-Soares; Stephen J. Rith-Najarian; Aristidis Veves; Nikki Coates; William Jeffcoate; Nicola Leech; Tom Fahey; Jayne Tierney

BackgroundDiabetes–related lower limb amputations are associated with considerable morbidity and mortality and are usually preceded by foot ulceration. The available systematic reviews of aggregate data are compromised because the primary studies report both adjusted and unadjusted estimates. As adjusted meta-analyses of aggregate data can be challenging, the best way to standardise the analytical approach is to conduct a meta-analysis based on individual patient data (IPD).There are however many challenges and fundamental methodological omissions are common; protocols are rare and the assessment of the risk of bias arising from the conduct of individual studies is frequently not performed, largely because of the absence of widely agreed criteria for assessing the risk of bias in this type of review. In this protocol we propose key methodological approaches to underpin our IPD systematic review of prognostic factors of foot ulceration in diabetes.Review questions;1. What are the most highly prognostic factors for foot ulceration (i.e. symptoms, signs, diagnostic tests) in people with diabetes?2. Can the data from each study be adjusted for a consistent set of adjustment factors?3. Does the model accuracy change when patient populations are stratified according to demographic and/or clinical characteristics?MethodsMEDLINE and EMBASE databases from their inception until early 2012 were searched and the corresponding authors of all eligible primary studies invited to contribute their raw data. We developed relevant quality assurance items likely to identify occasions when study validity may have been compromised from several sources. A confidentiality agreement, arrangements for communication and reporting as well as ethical and governance considerations are explained.We have agreement from the corresponding authors of all studies which meet the eligibility criteria and they collectively possess data from more than 17000 patients. We propose, as a provisional analysis plan, to use a multi-level mixed model, using “study” as one of the levels. Such a model can also allow for the within-patient clustering that occurs if a patient contributes data from both feet, although to aid interpretation, we prefer to use patients rather than feet as the unit of analysis. We intend to only attempt this analysis if the results of the investigation of heterogeneity do not rule it out and the model diagnostics are acceptable.DiscussionThis review is central to the development of a global evidence-based strategy for the risk assessment of the foot in patients with diabetes, ensuring future recommendations are valid and can reliably inform international clinical guidelines.


BMJ Open | 2016

An investigation of routes to cancer diagnosis in 10 international jurisdictions, as part of the International Cancer Benchmarking Partnership: survey development and implementation

David Weller; Peter Vedsted; Chantelle Anandan; Alina Zalounina; Evangelia Fourkala; Rakshit Desai; William R Liston; Henry Jensen; Andriana Barisic; Anna Gavin; Eva Grunfeld; Mats Lambe; Rebecca Jane Law; Martin Malmberg; Richard D Neal; Jatinderpal Kalsi; Donna Turner; Victoria White; Martine Bomb; Usha Menon

Objectives This paper describes the methods used in the International Cancer Benchmarking Partnership Module 4 Survey (ICBPM4) which examines time intervals and routes to cancer diagnosis in 10 jurisdictions. We present the study design with defining and measuring time intervals, identifying patients with cancer, questionnaire development, data management and analyses. Design and setting Recruitment of participants to the ICBPM4 survey is based on cancer registries in each jurisdiction. Questionnaires draw on previous instruments and have been through a process of cognitive testing and piloting in three jurisdictions followed by standardised translation and adaptation. Data analysis focuses on comparing differences in time intervals and routes to diagnosis in the jurisdictions. Participants Our target is 200 patients with symptomatic breast, lung, colorectal and ovarian cancer in each jurisdiction. Patients are approached directly or via their primary care physician (PCP). Patients’ PCPs and cancer treatment specialists (CTSs) are surveyed, and ‘data rules’ are applied to combine and reconcile conflicting information. Where CTS information is unavailable, audit information is sought from treatment records and databases. Main outcomes Reliability testing of the patient questionnaire showed that agreement was complete (κ=1) in four items and substantial (κ=0.8, 95% CI 0.333 to 1) in one item. The identification of eligible patients is sufficient to meet the targets for breast, lung and colorectal cancer. Initial patient and PCP survey response rates from the UK and Sweden are comparable with similar published surveys. Data collection was completed in early 2016 for all cancer types. Conclusion An international questionnaire-based survey of patients with cancer, PCPs and CTSs has been developed and launched in 10 jurisdictions. ICBPM4 will help to further understand international differences in cancer survival by comparing time intervals and routes to cancer diagnosis.

Collaboration


Dive into the Chantelle Anandan's collaboration.

Top Co-Authors

Avatar

Aziz Sheikh

University of Edinburgh

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Raj Bhopal

University of Edinburgh

View shared research outputs
Top Co-Authors

Avatar

Rob Elton

University of Edinburgh

View shared research outputs
Top Co-Authors

Avatar

Azeem Majeed

Imperial College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David Weller

University of Edinburgh

View shared research outputs
Top Co-Authors

Avatar

Ashly Black

University of Edinburgh

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge